Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 1
2005 5
2006 6
2007 7
2008 3
2009 8
2010 16
2011 10
2012 15
2013 23
2014 27
2015 21
2016 28
2017 47
2018 62
2019 72
2020 72
2021 83
2022 107
2023 121
2024 128
2025 149
2026 31

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

935 results

Results by year

Filters applied: . Clear all
Page 1
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E, Zwaan CM, Grove CS, Stone R, Shami PJ, Mantzaris I, Greenwood M, Shukla N, Cuglievan B, Kovacsovics T, Gu Y, Bagley RG, Madigan K, Chudnovsky Y, Nguyen HV, McNeer N, Stein EM. Issa GC, et al. Among authors: gu y. J Clin Oncol. 2025 Jan;43(1):75-84. doi: 10.1200/JCO.24.00826. Epub 2024 Aug 9. J Clin Oncol. 2025. PMID: 39121437 Free PMC article. Clinical Trial.
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM. Issa GC, et al. Among authors: gu y. Nature. 2023 Mar;615(7954):920-924. doi: 10.1038/s41586-023-05812-3. Epub 2023 Mar 15. Nature. 2023. PMID: 36922593 Free PMC article. Clinical Trial.
Multimodal AI generates virtual population for tumor microenvironment modeling.
Valanarasu JMJ, Xu H, Usuyama N, Kim C, Wong C, Argaw P, Ben Shimol R, Crabtree A, Matlock K, Bartlett AQ, Bagga J, Gu Y, Zhang S, Naumann T, Fox BA, Wright B, Robicsek A, Piening B, Bifulco C, Wang S, Poon H. Valanarasu JMJ, et al. Among authors: gu y. Cell. 2026 Jan 22;189(2):386-400.e19. doi: 10.1016/j.cell.2025.11.016. Epub 2025 Dec 9. Cell. 2026. PMID: 41371214 Free article.
The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer.
Taifour T, Attalla SS, Zuo D, Gu Y, Sanguin-Gendreau V, Proud H, Solymoss E, Bui T, Kuasne H, Papavasiliou V, Lee CG, Kamle S, Siegel PM, Elias JA, Park M, Muller WJ. Taifour T, et al. Among authors: gu y. Immunity. 2023 Dec 12;56(12):2755-2772.e8. doi: 10.1016/j.immuni.2023.11.002. Epub 2023 Nov 30. Immunity. 2023. PMID: 38039967 Free article.
A whole-slide foundation model for digital pathology from real-world data.
Xu H, Usuyama N, Bagga J, Zhang S, Rao R, Naumann T, Wong C, Gero Z, González J, Gu Y, Xu Y, Wei M, Wang W, Ma S, Wei F, Yang J, Li C, Gao J, Rosemon J, Bower T, Lee S, Weerasinghe R, Wright BJ, Robicsek A, Piening B, Bifulco C, Wang S, Poon H. Xu H, et al. Among authors: gu y. Nature. 2024 Jun;630(8015):181-188. doi: 10.1038/s41586-024-07441-w. Epub 2024 May 22. Nature. 2024. PMID: 38778098 Free PMC article.
An extra-erythrocyte role of haemoglobin body in chondrocyte hypoxia adaption.
Zhang F, Zhang B, Wang Y, Jiang R, Liu J, Wei Y, Gao X, Zhu Y, Wang X, Sun M, Kang J, Liu Y, You G, Wei D, Xin J, Bao J, Wang M, Gu Y, Wang Z, Ye J, Guo S, Huang H, Sun Q. Zhang F, et al. Among authors: gu y. Nature. 2023 Oct;622(7984):834-841. doi: 10.1038/s41586-023-06611-6. Epub 2023 Oct 4. Nature. 2023. PMID: 37794190 Free PMC article.
Osteopontin is a therapeutic target that drives breast cancer recurrence.
Gu Y, Taifour T, Bui T, Zuo D, Pacis A, Poirier A, Attalla S, Fortier AM, Sanguin-Gendreau V, Pan TC, Papavasiliou V, Lin NU, Hughes ME, Smith K, Park M, Tremblay ML, Chodosh LA, Jeselsohn R, Muller WJ. Gu Y, et al. Nat Commun. 2024 Oct 24;15(1):9174. doi: 10.1038/s41467-024-53023-9. Nat Commun. 2024. PMID: 39448577 Free PMC article.
935 results